RxDoctor Payments Data

Lonnie Moore, NP

Family · Marks, MSNPI 1962852988

Payments from drug & device makers

$382in general payments, 2019–2025

Across 15 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$176
  • Nestle Healthcare Nutrition Inc.$63
  • Electromed, Inc.$56
  • Avanir Pharmaceuticals, Inc.$24
  • SK Life Science, Inc.$18
  • Lilly USA, LLC$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$382 in reported general payments places this provider in the 50th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,047
Medicare patients
72
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$28,523
LinzessLinaclotide17$13,239
Verapamil SrVerapamil Hcl14$1,360
Gabapentin115$1,306
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,195
Albuterol Sulfate HfaAlbuterol Sulfate48$1,189
Verapamil ErVerapamil Hcl24$1,088
Potassium Chloride59$1,027
Colchicine16$803
Omeprazole61$699
Atorvastatin Calcium77$648
Montelukast Sodium62$541
Famotidine41$528
Hydralazine Hcl28$494
Metoprolol Succinate22$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$176$28,52330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,007 family providers in Mississippi.

Other family in Marks

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →